EMA Authorised: Ranexa (previously Latixa) (ranolazine) — Menarini International Operations Luxembourg S.A. (MIOL)

View source ↗

Summary

The EMA authorises Ranexa (ranolazine) for angina pectoris with MIOL as the marketing author holder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Angina Pectoris

Drugs mentioned

• Ranexa (ranolazine)

Snippet

Status: Authorised. Therapeutic area: Angina Pectoris. MAH: Menarini International Operations Luxembourg S.A. (MIOL). Decision date: 10/08/2022